15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026

Page 9 of 10

7. Roivant Sciences Ltd. (NASDAQ:ROIV)

Greenlight Capital’s Stake: $45 Million 

Increase in Share Price Over Past Six Months: 51%

Roivant Sciences Ltd. (NASDAQ:ROIV) has been a consistent feature in the 13F portfolio of Greenlight Capital since the first quarter of 2024. Back then, this position comprised 4.1 million shares. By the third quarter of 2024, the fund had grown this holding to 5.3 million shares. After the first quarter of 2025, the fund started trimming this stake. Filings for the fourth quarter of 2025 show that the fund owned a little over 2 million shares in the firm, down close to 10% compared to filings for the third quarter of 2025. Roivant is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of medicines.

Roivant Sciences Ltd. (NASDAQ:ROIV) recently announced a $2.25 billion global settlement with Moderna regarding COVID-19 vaccine patents. This non-dilutive capital injection has significantly bolstered the balance sheet of the firm. Beyond the lead candidates, hedge funds are also focused on the IMVT-1402 and Batoclimab programs of the firm. In April, Roivant released positive Phase 3 results for Batoclimab in Thyroid Eye Disease. Analysts note that the unique positioning of IMVT-1402, an investigational anti-FcRn antibody, in the auto-immune market gives the firm a structural advantage over competitors like Argenx.

Page 9 of 10